A similar approach is increasingly relevant in HER2-positive breast cancer, where pCR is a key prognostic indicator associated with favorable outcomes.32 In HER2 + disease, TILs may serve as a valuable marker for identifying patients likely to achieve pCR and, consequently, better survival outcomes. The gene discussed is ERBB2; the disease is breast cancer.